Biochemistry, Genetics and Molecular Biology
Synapsin I
100%
Serine Protease
100%
Acute Phase Protein
100%
Adaptive Immunity
100%
Innate Immunity
100%
Enzyme
50%
Lipid
50%
B Cell
50%
Clinical Trial
50%
Elastase
50%
Metalloproteinase
50%
Metalloendopeptidase
50%
Lipid Raft
50%
Glucose Level
50%
Dendritic Cell
50%
Protease
50%
Proteinase Inhibition
50%
Third Trimester Pregnancy
50%
Cell Activity
50%
Antiinflammatory Activity
50%
Positive Feedback
50%
Interleukin 8
50%
Cell Damage
50%
Acute Phase Response
50%
Immunology and Microbiology
Adaptive Immune System
100%
Innate Immune System
100%
Acute Phase Protein
100%
Immunosuppression
100%
B Cell
50%
Neutrophil
50%
Antiinflammatory Activity
50%
Lipid Raft
50%
Interleukin 8
50%
Immune System
50%
Dendritic Cell
50%
Acute Phase Response
50%
Cell Activity
50%
Cell Damage
50%
Third Trimester Pregnancy
50%
Positive Feedback
50%
Proteinase Inhibition
50%
Glucose Level
50%
Keyphrases
Antitrypsin
100%
Innate Immune Response
100%
Adaptive Immune Response
100%
Acute Phase Proteins
100%
Immunosuppression
18%
High Glucose
9%
Clinical Trials
9%
Anti-inflammatory Activity
9%
Clinical Safety
9%
B Lymphocytes
9%
Cholesterol
9%
Lipid Rafts
9%
Potential Gains
9%
Interleukin-8
9%
Anti-inflammatory Agents
9%
Immune System
9%
Clinical Grade
9%
Dendritic Cells
9%
Elastase Inhibition
9%
Neutrophil Elastase
9%
Lymphocyte Activation
9%
Acute Phase Response
9%
Tolerogenic
9%
Serine Protease
9%
Alpha-1 Antitrypsin Deficiency
9%
Protease Family
9%
Advanced Age
9%
Positive Feedback Loop
9%
Trypsin Treatment
9%
Danger-associated Molecular Patterns
9%
Relative Activity
9%
Release Criteria
9%
Agent Behavior
9%
Inflammatory Parameters
9%
Innocent Bystanders
9%
Circulating Lipids
9%
Metallopeptidase
9%
Cell Injury
9%
Third Trimester
9%
Serine Protease Inhibition
9%
Lipid Particles
9%
Tumor Susceptibility
9%
Bystander Cells
9%
Novel Entities
9%
Bacterial Protease
9%
Viral Susceptibility
9%
Cell Activity
9%
Medicine and Dentistry
Adaptive Immunity
100%
Trypsin Inhibitor
100%
Innate Immunity
100%
Acute Phase Protein
100%
Synapsin I
100%
Immunosuppressive Treatment
18%
Serine Proteinase
18%
Infection
9%
Clinical Trial
9%
Neutrophil
9%
B Lymphocyte
9%
Immune System
9%
Elastase
9%
Dendritic Cell
9%
Acute Phase Response
9%
Proteinase Inhibition
9%
Cell Damage
9%
Metalloproteinase
9%
Lipid Raft
9%
Antiinflammatory Agent
9%
Third Trimester Pregnancy
9%
Cancer Susceptibility
9%
Antiinflammatory Activity
9%
Smoke
9%
Cell Activity
9%
Proteinase
9%
Alpha Antitrypsin Deficiency
9%
Interleukin 8
9%
Positive Feedback
9%
Pharmacology, Toxicology and Pharmaceutical Science
Trypsin Inhibitor
100%
Synapsin I
100%
Acute Phase Protein
100%
Serine Proteinase
18%
Injury
9%
Proteinase
9%
Infection
9%
Clinical Trial
9%
Anti-Inflammatory Drug
9%
Interleukin 8
9%
Antiinflammatory Agent
9%
Elastase
9%
Alpha Antitrypsin Deficiency
9%
Metalloproteinase
9%
Cancer Susceptibility
9%